Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Geez, I ran out of the "patience" part a Long Time Ago. Happy Memorial Day.

[ATLdoogie]

Hey microcapbiotech........in your post did you mean patients or patience? Both apply to MRKR lol. Imagine being one of these new migrants trying to learn English.

[learningcurve2020]

Anyone think they'll update this to include Vera's roll at Marker or just leave it as is?

https://www.allovir.com/our-people/juan-f-vera-md

[learningcurve2020]

Guess the Marker CEO hasn't gotten around to updating yet.

https://www.linkedin.com/in/juan-vera-a30b3b16a

[jobynimble]

Stop making off topic posts, last warning…

[learningcurve2020]

Something about unlocking value by selling the facility for cost because they should've never gotten into manufacturing that the directors must've approved in the first place. Everyone knows the $19mn ain't gonna get them "Runway" to 2025. Restructure sounds exciting! Eye rolls.

[GoIrish1776]

Agreed. Was just recognizing that I had the same mixup. When you’re paid and paying, someone needs to check. Someone at the company needs to read the release and OK it.

I think highly of Vera. His choice to do this kind of stuff is a bit suspect.

[Phantom Lord]

I totally understand Proactive's mix up. I still won't excuse it given Marker paid them. There are plenty of other resources available to them. They could have taken two seconds to double check that they got it right. Instead they rushed it. It was a three minute interview and a three paragraph "article." You can't mess that up. Especially when the company has paid you.

[GoIrish1776]

When you listen, Vera sounds like he says $90m. It’s just an accent issue I suspect. It sounds like learning is going to get part of his strategic review presentation. I doubt it will matter much but hopefully we’ll have clear timelines and maybe some insight into a path to a sustainable business.

[microcapbiotech]

As long as I am rambling on, I'll go on. I've been investing in stocks since the 1980's.
I have always thought of an individual stock price as a rubberband.
That rubberband is almost NEVER non stretched and at it's "fair" price (although conventional market wisdom says stocks always find their natural level). That rubberband is almost ALWAYS stretched either too high or too low because of all the varied market influences on it.
Day traders stretch it too high, Short sellers stretch it too low, options buyers and sellers can stretch it either way, greed stretches it too high, fear stretches it too low, good news or a good earnings report breeds enthusiasm and optimism and greed, and the opposite breeds doubt and pessimism and fear.
Discord and other like sites and memes and talking heads on TV all stretch that rubberband one way or the other.
My point is, don't buy when it has a "reason" to be artificially stretched high, and vice versa.
The same rubberband theory also effects and applies to P/E ratios and P/E/G ratios.
It's all in the eye of the beholder.
GO MRKR.

[learningcurve2020]

Well, that's just the world nobody ever reports on.

[microcapbiotech]

Juan Vera said that in the NEXT FEW WEEKS an update is coming.
Before I go any further, look at what happened when the Cellready news came out.
It's what almost Always happens. The stock price shot up a bit, then the day traders jump in and out and in and out (which is why you got the large volume for a couple of days), and they drive the price up even more to an artificially high price (over $1.60 post Cellready news), and they they take their gained (and lost for some) money and leave, and then the price drifts back down to settle at it's next "real" (non day trader influenced) price.
So when Juan Vera does his thing in the NEXT FEW WEEKS (his words), the same thing will most likely happen again.
I think, if you want to "trade" or even hold more, either buy before the news or within a few minutes of it.
If you buy well after the news, just like with the Cellready news, you may wind up watching your high buy in price drift back down somewhat.
Good Luck to Juan and Marker and patients and investors.

[Phantom Lord]

lol. Yea, that's the big error I alluded to. You'd think they would get it right since they were paid to write that trash.

[microcapbiotech]

Thank You Proactive for giving MRKR an extra 71 million dollars. It's 19 not 90, and we paid these dumbasses good money for (as Phantom pointed out) will be viewed by almost no one.

[Phantom Lord]

Should be plenty of time if they truly are prepared to solely focus on their trials. Based on recent events it does seem that is the case. We knew the company has been conducting a strategic review of their clinical programs but I guess the one thing I got from that interview is it sounds like we should be getting an update on that review in the next few weeks. Hopefully it impresses.

[microcapbiotech]

I feel like I'm in the Twilight Zone ... you ... me .... and LC ... all agree on something.
That proves that miracles can happen ... maybe one will happen with MRKR.
They did their deal, they got their money, they got about a year and a half to impress enough for real money to start flowing in based on something other than just hope.

[Phantom Lord]

Not only did they pay for what amounts to nothing, Proactive made a pretty HUGE error in the "article" that shows their incompetence. Not a great look. That being said, it's not like anyone will see this anyways.

[microcapbiotech]

On this we can agree. I didn't like it 2 years ago and said so then. I don't like it now. Usually a VERY BIG red flag. Having said that, I have no choice (in my mind) but to hold and hope.
I am in way too deep to sell at a large loss. Would rather stick it out and lose it all.

[learningcurve2020]

Agreed. It's like they're chasing OTC retail investors. Usually a red flag.

[microcapbiotech]

Thank You, I guess any press is good press? ... BUT we went through this kind of thing a couple of years ago with ex-CEO PH and MRKR ... it does not look good to have to PAY money to a "Hype the Company" outfit. I think last time it was Redchip or somelike like that, this time it's Proactive.
If you Got the Goods or if your press info was relevant enough, it would be disseminated by "normal" news outlets, you would NOT have to PAY for your information to be published.
In general, companies that Pay for Hype are garbage companies and they know it.

[jobynimble]

Watch Juan Vera, President and CEO at Marker Therapeutics, Inc., join Natalie Stoberman from the @proactive_NA studios to discuss Marker’s strategic partnership with CellReady, enhancing #immunotherapy manufacturing and putting focus on Marker’s clinical development. https://t.co/JPNihYvXB2

— Marker Therapeutics, Inc. (@MRKRTherapeutic) May 24, 2023

[jobynimble]

$MRKR Marker Therapeutics' adds cell and gene therapy manufacturing to immunotherapy platform https://t.co/e8Pw0NimwC @MRKRTherapeutic #MRKR

— Proactive USA (@proactive_NA) May 24, 2023

[learningcurve2020]

Very helpful, thanks. I'm continuing my research on the subject. I wish the company would give retail an IP portfolio presentation.

[Cincinnati Kid]

Learningcurve I'm responding to your insinuation that a unique manufacturing process is not valuable if it delivers something that can be found in nature.

Hope this helps.

A unique manufacturing process is patentable and, assuming it is more efficient at producing something found in nature than other processes, those patents would provide meaningful protection against competition.

The important thing to know about biologic drugs, such as T cells, is that that "the process is the product" which is described here https://archive.bio.org/articles/how-do-drugs-and-biologics-differ

Here is a relevant excerpt from info in that link:

"Drugs generally have well-defined chemical structures, and a finished drug can usually be analyzed to determine all its various components. By contrast it is difficult, and sometimes impossible, to characterize a complex biologic by testing methods available in the laboratory, and some of the components of a finished biologic may be unknown.

Therefore, for biologics, "the product is the process." Because the finished product cannot be fully characterized in the laboratory, manufacturers must ensure product consistency, quality, and purity by ensuring that the manufacturing process remains substantially the same over time."

[learningcurve2020]

I see, so now speculating about offers they may have had is asinine. That sure says a lot for their IP! LOL. I mean how foolish can an "investor" be to shut down every comment that's not about chasing this or that disease with specific antigens.

Remaining on the Nasdaq did absolutely nothing! And, they're going to get bumped off to the OTC anyway. Why? Because they have almost nothing to speculate on right now and because they need to save every penny they can. Watch and learn.

You have no idea if anyone made an offer that was turned down or went bad. PERIOD. That's because management doesn't think they need to tell retail just like they didn't ask for approval on this facility buyout by a director, of all things. LOL.

[microcapbiotech]

Honestly, your asinine replies are getting tiresome. You make a statement like "They should've forgone the rs and brought in a partner with cash." without the slightest level of deeper thinking.
Examine your statement, "They should've forgone the rs". Anybody with a functioning brain realizes that IF they "forgone the rs" they would have been delisted by Nasdaq.
WOULD THAT HAVE BEEN BETTER FOR THE COMPANY AND SHAREHOLDERS?
Yes or No.
"and brought in a partner with cash." Us adults that live in the real world understand that in real life (not the fairytale make believe world you seem to live in) you don't get to just snap your fingers and make a cash partner just appear. If there was none to be had, then there was none to be had, PERIOD.
Before you go on your next ludicrous rant, WHATEVER reasons there was none to be had, those reasons are IRRELEVANT.
They could find no "cash partner", they did not want to be delisted (DUH) so they HAD NO CHOICE but to do a R/S.
After I click "Submit" I will return you to the IGNORE status so I don't have to waste my time reading childish gibberish.

[learningcurve2020]

100% false. They should've forgone the rs and brought in a partner with cash. If no partner to be had that must mean the chances of this product showing efficacy is slim to none.

[microcapbiotech]

"What Marker needs to do is show that it works." 100% True.
"The restructuring gave them as good of a shot as any to figure this situation out. It was a very good move." Also 100% True.
Now, we wait and see.
Thanks.

[learningcurve2020]

It was a terrible move to do a border-line reverse split with no positive news that sent the stock price plummeting even further and left shareholders with heavy loses. For such a "Cheap" process they sure did blow through a lot of cash with little to show for it. Hmm

[learningcurve2020]

"Cheap Cheap Cheap" seems to be the messaging. But yet the trials move in slow motion.

[learningcurve2020]

How long before this page comes down?

"Marker’s unique manufacturing process"

[learningcurve2020]

But it is found in nature it's just that Marker claims to have a way to target and accelerate the process more efficiently. It's basically a training process, is it not?

[GoIrish1776]

FWIW, I think the comparison is the wrong construct. It’s psoriasis relative to cancer. What Marker needs to do is show that it works and provides value in some area of cancer (alone or in combination) and then it can extend. It needs to communicate that story and execute on it. It will likely be significantly more complicated than a psoriasis treatment given the heterogeneity of cancers but the treatment needs to find its place in the field, e.g., as an adjuvant keeping cancer in remission, keeping cancer from escape coupled with heavier handed treatments, as a stand-alone treatment with much higher doses for situations with low cancer presence, etc. MRKR needs to prove something that is part of a larger story and if they did, the market cap will likely follow in my opinion. PS The low valuation now is an issue of belief and path to profitability. The market doesn’t think the technology works or works well enough and there isn’t a path going forward that seems plausible. The restructuring gave them as good of a shot as any to figure this situation out. It was a very good move.

[microcapbiotech]

ONCE AGAIN, THANK YOU. "It's obviously a long shot but given how cheap Marker's therapy is to produce, the low bar for approval (IMO), and the CR we saw in the PI I think it at least warrants further exploration. The more shots on goal the better."
After reading that, I think I would agree.

[GMA13]

Dr Vera commented on Pancreatic Cancer as follows, in case you missed my earlier post.

On May 18, 2023, at 6:31 PM, Juan Vera <[e-mail]> wrote:

Thank you _ _ _ _ _ _ _.

I will keep you posted as we know more about the grant support for the pancreatic study and the path forward. Thank you for your feedback.
Best
J


From: _ _ _ _ _ _ _ _
< _ _ _ _ _ _ _ >
Sent: Thursday, May 18, 2023 4:06:32 PM
To: Juan Vera <[e-mail]>
Subject: Pancreatic Cancer

Hi Again Dr. Vera,

There seems to be an overwhelming consensus, from my scientifically knowledgeable colleagues, that MRKR should consider more than just 1 new Antigen and the New Manufacturing Facility in order to effectively challenge Pancreatic Cancer.

Given the prior Pancreatic Cancer test outcome, some of the Antigens utilized may need to be different ones to be combined with the new proposed Antigen.

In any case, best of luck!

Best regards,
_ _ _ _ _ _ _ _
Shareholder

[Phantom Lord]

For context global psoriasis market is roughly $25B annually (SOURCE). Worldwide roughly 125M people suffer from it.

The global AML market size is roughly between $1B and $2B annually. I’m seeing different numbers. (SOURCE 1 SOURCE 2). About 20k cases each year in the US (SOURCE). Note that this is total, not post-transplant. Of AML cases I think roughly 80% of them ultimately end up having a transplant.

The global Non-Hodgkin Lymphoma market is currently roughly $8.5B annually (SOURCE 1 SOURCE 2 SOURCE 3). Roughly 80k cases each year in the US (SOURCE). Note here that Marker is specifically targeting patients who have failed or are ineligible for CAR-T.

The global pancreatic cancer market is roughly $2B annually. (SOURCE 1 SOURCE 2). Roughly 65k cases each year in the US (SOURCE).

I fully believe it is worth going after pancreatic cancer. Below is reposted from my previous post regarding my thoughts on pancreatic:

"This one gets a lot of flak from people saying they shouldn't be pursuing it. Ultimately, I disagree. They might consider putting it on hold to save as much money as they can but I believe it makes sense to pursue. Pancreatic cancer is basically a death sentence and treatment options are limited. I believe the bar to an approval is relatively low. The PI done at BCM yielded one CR. If I remember correctly that CR was noted well beyond where it would have been seen with chemo alone. It's obviously a long shot but given how cheap Marker's therapy is to produce, the low bar for approval (IMO), and the CR we saw in the PI I think it at least warrants further exploration. The more shots on goal the better."

is MRKR trying to make money (profits) or are they trying to be altruistic even if the market size (and potential profits) are small?

I can't 100% answer this. I can only provide my opinion based on what I know about the people currently in charge and I fully believe that Vera and Wilson, first and foremost, care about the patients and trying to provide therapies for unmet needs. It does mean smaller patient populations which means potentially less profits. Especially with how cheap the therapy is to produce. That being said, they can't really be focused on profits right now anyways as their main focus needs to be showing success in their current trials. Do right by the patients. If that works out they will have done right by they shareholders.

[Cincinnati Kid]

https://markertherapeutics.com/science/manufacturing/

[Cincinnati Kid]

What's not found in nature is the process of removing a population cells from a person, enhancing the outgrowth of cells that recognize a peptide library that simulates what is found on cancer cells, and putting those cells into a cancer patient.

[microcapbiotech]

You know, speaking of MRKR and MRKR stock, I am reminded of an old saying.
I like old sayings because if they were not true, they would not stick around and be retold for many many generations.
"It is better to keep your mouth shut and be thought a fool, than to open it and remove all doubt."
GO MARKER

[microcapbiotech]

If it is not an AI Chatbot programed intentionally to be argumentative and obnoxious, then we should give it an award because it does one heck of a job at it.
Whether "there's likely subtleties" or not is 100% IRRELEVANT because ...........
AGAIN, for the SECOND TIME ........ and perhaps it will read and comprehend this:
"EVERY SINGLE large firm that currently holds MRKR HAS been HOLDING MRKR for many quarters ALREADY when MRKR was WELL BELOW $5 ALREADY. MRKR was and had been BELOW $5 for a long time before the reverse split, Sooooo Mr. can't figure out the obvious for yourself, IF IF IF those institutions you imply won't be allowed to hold MRKR because it is below $5, then it is OBVIOUS that they would NOT have been allowed to hold MRKR in the past, WHICH THEY DID. DUH!."
SO, EVEN IF there ARE "subtitles", they would NOT have been allowed to hold MRKR in the past ......... and THEY DID.

[learningcurve2020]

Yeah, that's a head scratcher, I know. LOL

[learningcurve2020]

Will someone please explain to me why we shouldn't be concerned that, if successful, Marker's T cell IP won't be challenged on the bases of being non genetically engineered and as a product of nature?

[jobynimble]

Likely? LOL!!!! Just make stuff up to see if you get a rise out of it, pathetic…

[learningcurve2020]

There's likely subtleties in the rules where buying above $5 that drops below is a hold...at least for a while.

[microcapbiotech]

Howdy Phantom, Please don't spend time doing research on this question, I'm not looking for an exact answer, just looking for your general opinion which I know from reading your posts for years you already have this info pretty close in your head.
In the past, when I questioned why a psoriasis company was worth so much more than a AML cancer company in roughly the same stage of development ... your lesson was ... SIZE OF THE MARKET .... which of course makes sense.
So, my question (or actually two part questions) is/are this:
IF AML market size is a 1 and psoriasis market size is a 10, can you give a rough estimate of what number the lymphoma market size would be?
Also, same question for pancreatic market?
This is the part two part: You have said many times in the past that AML Active was difficult indication to go after ... and you have said that pancreatic was also a difficult indication to go after, so, based on your number for the pancreatic market from the above question, and based on the Difficulty of pancreatic, do you think (even if they somehow are successful) that it is worth spending more money on pancreatic when AML Adjuvant and Lymphoma are futher along and may be a better market size?
I guess I can sum it up by asking, is MRKR trying to make money (profits) or are they trying to be altruistic even if the market size (and potential profits) are small?
Thank You

[microcapbiotech]

Concerning this being allowed to buy below a $5 price.
Yes, some institutions and mutual funds have their own rules in their prospectus about buying limitations.
Some stay away from low dollar prices to avoid being too close to the threshold for being delisted (just to give themselves more comfortable breathing room).
Some stay away because they want a Much Larger potential bandwagon of buyers buying right along with them in order to keep the share price high and going up, and THEY KNOW that MOST of the investment community money GOES TO above $5 stocks, and therefore there will be MUCH LESS potential for investment community money to go into the cheaper stock to drive the price up.
MOST stay away from penny stocks or anything near that. That's nothing new.
BUT, this statement of: "The firms holding Marker have rules so we'll see the next quarter or two if they have the $5 rule." , is absolutely ludicrous (no surprise) because all you have to do is THINK.
EVERY SINGLE large firm that currently holds MRKR HAS been HOLDING MRKR for many quarters ALREADY when MRKR was WELL BELOW $5 ALREADY. MRKR was and had been BELOW $5 for a long time before the reverse split, Sooooo Mr. can't figure out the obvious for yourself, IF IF IF those institutions you imply won't be allowed to hold MRKR because it is below $5, then it is OBVIOUS that they would NOT have been allowed to hold MRKR in the past, WHICH THEY DID. DUH!.

[learningcurve2020]

But that didn't even come close to working. They knew the sale of the facility was in play for $19 million so there'd be nothing left to speculate on but a failed T cell trial.

[microcapbiotech]

OH MY GOD - How MANY times must we (me - you - others) answer the SAME DAMN QUESTION?
Question: So why the reverse split then?
Answered MANY times: To avoid delisting from the Nasdaq (it's F...ing OBVIOUS).

[Phantom Lord]

So why the reverse split then?

To avoid delisting from the Nasdaq.

it depends on the firms own rules. The firms holding Marker have rules so we'll see the next quarter or two if they have the $5 rule.

We will never know what the firm's rules are. You are implying that if they don't buy more then they have a rule stating they can't buy under $5. Even you of all people know that doesn't mean anything. You will never know what their rules are. Let me take a page out of your playbook here. Eye roll.

[learningcurve2020]

So why the reverse split then?

Yes we have, and it depends on the firms own rules. The firms holding Marker have rules so we'll see the next quarter or two if they have the $5 rule.